News

“Prometheus had another record year in 2008, our 12th consecutive year of sales growth,” said Joseph M. Limber, President And Chief Executive Officer of Prometheus. “In addition, we

Vetter Pharma-Fertigung, a provider of aseptically pre-filled injection systems, has formed a new subsidiary, Vetter Pharma International. With a scheduled launch date of April 1, 2009, Vetter Pharma

GVK Biosciences, an Indian contract research organization, has obtained approval from the Ministry of Health of Turkey for bioequivalence studies. This approval enables GVK Biosciences to cater to

The companies will also continue joint product development activities ensuring customers have continued access to new coagulation technology. “Our shared value to deliver quality products and services that

Net sales for the fourth quarter of 2008 were $2.2 million, down $1.2 million, or 31.6% from $3.3 million reported in the fourth quarter of 2007. Operating loss

Medivation, a biopharmaceutical company, has received the FDA approval to begin a pivotal Phase III trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant

Genzyme, a biotechnology company, has announced that the European Medicines Agency’s Committee for Human Medicinal Products has adopted a positive opinion for the marketing authorization of the new

Joining Medtronic are Ardian’s three existing investors: Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners, as well as new investor Emergent Medical Partners. Andrew Cleeland, president and

Under the agreement, clinical laboratory customers around the world continue to have access to the largest portfolio of coagulation instruments and tests. The companies will also continue joint